CrannMed was established to unlock the potential of embolisation across a range of therapies. The power of embotherapy to improve patient outcomes in a very minimally invasive way is being proven across Osteoarthritis, Benign Prostate Hyperplasia (BPH), Uterine Fibroids and Bariatric applications. Embolisation has the potential to be a huge part of the future treatment paradigm for these diseases and CrannMed is determined to play a part in developing these solutions.
Embolisation is a minimally invasive procedure in which the blood supply to a specific location is restricted or stopped. The technique can be used to disrupt tumour growth by shutting down the vascular supply lines needed for growth, to control internal bleeding or deactivate nerve endings surrounding a particular target.
CrannMed is developing a resorbable embolic particles and a custom delivery catheter for the treatment of Knee Osteoarthritis.
CrannMed is based in Galway, Ireland and was founded in 2018 by Liam Farrissey. The CrannMed team has a strong balance of Commercial, Clinical and Product Development skills. CrannMed has also built a strong clinical network of world leading embolisation specialists.